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Abstract
Arsenic is a wide spread carcinogen associated with several kinds of cancers including skin, lung, bladder, and liver cancers.
Lung is one of the major targets of arsenic exposure. Angiogenesis is the pivotal process during carcinogenesis and chronic
pulmonary diseases, but the role and mechanism of arsenic in regulating angiogenesis remain to be elucidated. In this study
we show that short time exposure of arsenic induces angiogenesis in both human immortalized lung epithelial cells BEAS-
2B and adenocarcinoma cells A549. To study the molecular mechanism of arsenic-inducing angiogenesis, we find that
arsenic induces reactive oxygen species (ROS) generation, which activates AKT and ERK1/2 signaling pathways and increases
the expression of hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF). Inhibition of ROS
production suppresses angiogenesis by decreasing AKT and ERK activation and HIF-1 expression. Inhibition of ROS, AKT and
ERK1/2 signaling pathways is sufficient to attenuate arsenic-inducing angiogenesis. HIF-1 and VEGF are downstream
effectors of AKT and ERK1/2 that are required for arsenic-inducing angiogenesis. These results shed light on the mechanism
of arsenic in regulating angiogenesis, and are helpful to develop mechanism-based intervention to prevent arsenic-induced
carcinogenesis and angiogenesis in the future.
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Introduction
Arsenic is a well-documented carcinogen associated with hu-
man lung, skin, urinary bladder, kidney and liver cancers [1–3].
Arsenic causes DNA-strand break, loss of DNA methylation,
cellular endocrine disorder and cell transformation [4–9]. Arsenic
also induces oxidative stress, genotoxic damage, DNA repair
inhibition, epigenetic events and activation of certain signal
transduction pathways leading to aberrant gene expression [10].
The WHO sets the maximum safe level of arsenic at 0.01 mg/L,
while arsenic levels in water in some areas can be up to several
thousand times higher than the limit [11]. The lung cancer is
highly associated with arsenic exposure [1,12,13]. In addition to
lung cancer, arsenic exposure also leads to other cancers and
non-malignant pulmonary diseases including chronic bronchitis
and chronic obstructive pulmonary diseases (COPD) [14].
However, the mechanisms of arsenic exposure leading to the
lung carcinogenesis and other pulmonary diseases remain to be
elucidated.
Angiogenesis is the process that new capillaries are generated
from the pre-existing vasculature which plays a pivotal role in the
initiation of carcinogenesis and tumor progress, vascular diseases,
and various ischemic and inflammatory diseases [15,16]. Tumor
cannot grow without angiogenesis when it reaches 1,2m mi n
diameter [17]. Angiogenesis is also a prominent feature of the
structural tissue remodeling that occurs in the chronic airway
diseases including COPD, in which the angiogenesis/angiostatic
balance is affected [18,19]. VEGF is the most potent angiogenic
factor. Our previous studies demonstrated that arsenic induced
VEGF expression in human prostate cancer cells and tumor
angiogenesis [20,21]. Acute arsenic treatment also induced VEGF
expression in human microvascular endothelial cells through the
induction of heme oxygenase-1 gene expression [22]. It has been
reported that sodium arsenite (arsenic) treatment induced
angiogenesis responses using the chick chorioallantoic membrane
(CAM) model [23]. Recent study showed that the chronic ex-
posure of arsenic in drinking water caused both liver angiogenesis
and pathogenic liver sinusoidal endothelial cell capillarization in
mice mediated by sphingosine-1-phosphate type 1 receptor in
endothelial cells [24]. However, it is unknown whether acute
arsenic exposure may affect epithelial cells to induce angiogenesis
in vivo.
In this study, we used human immortalized normal lung
epithelial cells BEAS-2B to determine: 1) whether short time
exposure of arsenic induces angiogenesis; 2) what signaling path-
ways are involved in arsenic-inducing angiogenesis; 3) whether
VEGF and HIF-1 are required for arsenic-inducing angiogen-
esis. Given the important role of angiogenesis in lung cancer and
other arsenic-induced pulmonary diseases, these results may shed
light on the mechanism of arsenic-induced angiogenesis and help
to develop mechanism-based interventions to prevent carcino-
genesis and other diseases induced by arsenic in the future.
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Cell Culture
Human immortalized lung epithelial cells, BEAS-2B cells
(ATCC, Manassas, VA) were cultured in DMEM medium
supplemented with 10% fetal bovine serum (FBS) and 100 units/
ml penicillin, and 100 mg/ml streptomycin, and cultured at 37uC
in a 5% CO2 incubator. Human lung carcinoma cells, A549 cells
(ATCC, Manassas, VA) were maintained in RPMI 1640 medium
with 10% FBS and antibiotics as above.
Angiogenesis Assay
Fertilized chicken eggs (Charles River Laboratories Interna-
tional, Inc., Wilmington, MA) were incubated at 37uC for 9 days,
and angiogenesis assay was performed as we previously described
[25,26]. In brief, BEAS-2B cells and A549 cells were treated with
5 mM of sodium arsenic (Sigma, St. Louis, MO) for 5 h. Then cells
were trypsinized, resuspended, mixed with Matrigel, without or
with LY294002 (PI3K inhibitor) and U0126 (MAPK/ERK
inhibitor), and implanted onto the CAM at Day 9. Adenoviruses
carrying GFP, AKT-DN, HIF-1a siRNA (si HIF-1a), and catalase
were used to infect BEAS-2B cells at 30 MOI for 24 h before the
arsenic treatment. Similarly, BEAS-2B cells were transfected by
siRNA oligomers of siScrambled control (siSCR), MAPK siRNA
(siMAPK), and VEGF (siVEGF) at 50 nM for 24 h, then treated
by 5 mM sodium arsenite for 5 h. The siRNA against MAPK
was purchased from Qiagen. The sense sequence: UGCUGA-
CUCCAAAGCUCUGdTdT ; the antisense sequence: CAGAG-
CUUUGGAGUCAGCAdTdT . The On-Target plus Smartpool
siVEGF was from Dharmacon (Thermo Scientific, Pittsburgh, PA).
The four target sequences are: GCAGAAUCAUCACGAAGUG;
CAACAAAUGUGAAUGCAGA; GGAGUACCCUGAUGAG-
AUC; GAUCAAACCUCACCAAGGC. The cells were used for
angiogenesis assay. After 96 h of incubation, the tumor plugs were
trimmed off the CAM, and analyzed for angiogenesis response.
The number of blood vessels as the index of angiogenesis was
obtained by counting the branching of blood vessels in 2 square
millimeter, which was normalized to that of the control group.
Immunoblotting
BEAS-2B cells were starved for 24 h, then treated with sodium
arsenite for 2 h (for p-AKT, AKT, p-ERK1/2 and ERK2
expression) or 6 h (for HIF-1a and HIF-1b expression). To study
the effects of inhibitors, starved BEAS-2B cells were pre-treated
with diphenylene iodonium (DPI), catalase, LY294002, or U0126
for 30 min, then treated with 5 mM of sodium arsenite as above.
Total proteins were extracted from the cells using modified RIPA
buffer supplemented with protein inhibitors, separated by SDS-
PAGE, and blotted onto nitrocellular membrane. After blocking
with 5% nonfat milk for 2 h, the membranes were incubated with
the primary antibodies against HIF-1a, HIF-1b (BD, Franklin
Lakes, NJ), phospho-AKT, phospho-ERK1/2, AKT (Cell Signal-
ing Technology, Beverly, MA ), or ERK2 (Santa Cruz Bio-
technology, Santa Cruz, CA) overnight. The specific protein
signals were detected by incubation with horseradish peroxidase-
conjugated antibodies and with a chemiluninescence reagent
(Pierce, Rockford, IL) [27].
Dichlorofluorescein diacetate (DCFH-DA) Staining for ROS
Cells were treated with sodium arsenite at different concentra-
tions for 2 h, or treated with 5 mM sodium arsenite for different
time points as indicated, then cells were incubated with DCFH-
DA dye (Molecular Probe, Eugene, OR) for 15 min, washed with
PBS buffer, and fixed with10% formaldehyde solution. The
images were taken using a fluorescent microscope and analyzed as
we previously described [26,27].
Luciferase Assay
Cells were seeded in 12-well plate at 60% confluence and
cultured overnight. Cells were co-transfected with VEGF reporter
and b-galactosidase (b-gal) plasmids and cultured for 15 h.
Sodium arsenite at 0, 2.5, and 5 mM was added to the cells for
24 h. Luciferase assay was analyzed using luciferase assay system
(Promega, San Luis Obispo, CA). The activity of b-gal was used as
internal control of transfection efficiency. The relative luciferase
(luc) activity was calculated as the ratio of luciferase/b-gal, and
normalized to the control group [27].
RT-PCR
Total RNAs were extracted using Trizol reagent (Invitrogen,
Carlsbad, CA). Primers used for detecting VEGF and GAPDH are
as follows:
VEGF forward primer, 59-TCGGGCCTCCGAAACCATGA-39;
VEGF reverse primer, 59-CCTGGTGAGAGATCTGGTTC-39;
GAPDH forward primer, 59- CCACCCATGGCAAATTCC-
ATGGCA-39;
GAPDH reverse primer, 59-TCTAGACGGCAGGTCAGGT-
CCACC-39.
The amplification of VEGF was performed by PCR as pre-
viously described [27]. The expression levels of GAPDH were
used as an internal control.
Statistical Analysis
All values in this study were reported as mean 6 SD. Student’s
unpaired t test was used for statistical analyses. The values were
considered as significant difference at p,0.05.
Results
Arsenic treatment induces angiogenesis
Angiogenesis is a vital pathological process during tumorigen-
esis. To investigate whether short time treatment of arsenic has
effect on angiogenesis, human lung adenocarcinoma cell line A549
and immortalized normal human lung epithelial cells BEAS-2B
were treated with 5 mM of sodium arsenite for 5 h. Angiogenesis
assay was performed using the cells on the CAM model. Arsenic
treatment strongly increased A549 cell-inducing angiogenesis to
2.5-fold when compared to the untreated control cells (Fig. 1A).
Similarly, arsenic treatment also promoted BEAS-2B cells to
induce angiogenesis by more than 2-fold (Fig. 1B). These results
suggest that arsenic treatment induces angiogenesis in both
immortalized lung epithelial cells and lung cancer cells.
Arsenic activates AKT and ERK1/2 signaling pathways,
and increases the expression of HIF-1a and VEGF
AKT (also known as Protein kinase B) is a serine/threonine
kinase. The other important parallel signaling pathway is ex-
tracellular signal-regulated kinase (ERK). We showed that ar-
senic at 5 mM increased AKT and ERK1/2 activation in both
A549 and BEAS-2B cells (Fig. 2A), suggesting that arsenic can
activate these two signaling pathways in lung epithelial and cancer
cells. To analyze the downstream effector of AKT and ERK1/2,
we tested whether the expression of HIF-1 was induced by arsenic.
HIF-1 is a heterodimeric transcription factor that is composed of a
constitutive-expressing HIF-1b subunit and an oxygen-sensitive
HIF-1a subunit [28]. A549 cells and BEAS-2B cells were treated
with different doses of arsenic. As shown in Fig. 2A, arsenic
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BEAS-2B cells. VEGF is a potent angiogenesis inducer that is
upregulated by HIF-1 through the binding of HIF-1 to its
promoter [29]. Similarly, VEGF transcriptional activation was
significantly increased by arsenic treatment (Fig. 2B), and VEGF
mRNA level was induced by arsenic treatment (Fig. 2C),
suggesting that arsenic induces VEGF expression at transcriptional
level.
AKT and ERK1/2 are required for arsenic-inducing
angiogenesis
Pre-treatment of BEAS-2B cells with PI3K and MAP kinase
inhibitors LY294002 and U0126 blocked the activation of
phospho-AKT or phospho-ERK induced by arsenic, and de-
creased arsenic-inducing HIF-1a but not HIF-1b protein levels
(Fig. 3A). This result suggests that both AKT and ERK1/2 are
required for arsenic-induced HIF-1 expression. To test whether
AKT and ERK are required for arsenic-inducing angiogenesis,
BEAS-2B cells were treated by LY294002 or U0126, and used
to do angiogenesis assay. We found that LY294002 or U0126
treatment inhibited angiogenesis by more than 50% when
compared to the control (Fig. 3B). To further specifically inhibit
AKT or ERK, the cells were infected with adenoviruses carrying
GFP (Ad-GFP) and AKT dominant negative (Ad-AKT-DN) to
specifically inhibit AKT activation; or transfected with scrambled
control siRNA and siMAPK to knockdown MAPK expression.
These cells were used to perform angiogenesis assay. Similar to the
effect of LY294002 and U0126 treatment, BEAS-2B cells treated
with Ad-AKT-DN or siMAPK showed significant inhibition of
angiogenesis responses with the reduction to 50% and 70% as
compared to those of the Ad-GFP or siScrambled control group,
respectively (Fig. 3C). These results further confirm that AKT and
ERK1/2 are required for arsenic-inducing angiogenesis.
Arsenic induces reactive oxygen species (ROS) generation,
which is necessary for arsenic-inducing angiogenesis
Previous study showed that low level of sodium arsenic at
100 nM exposure for long time renders human keratinocytes
apoptotic resistant and induces ROS generation [30]. To study
whether short time exposure of arsenic may induce ROS levels,
BEAS-2B cells were treated with different doses of arsenic for 2 h,
or treated with 5 mM arsenic for 2 h and 4 h. As shown in Fig. 4A,
ROS production levels were higher with arsenic treatment at
10 mM than at 5 mM, and were higher with arsenic treatment at
5 mM for 4 h than for 2 h (Fig. 4B). These results demonstrate that
ROS are induced by arsenic treatment.
To further test whether arsenic-inducing ROS are required for
angiogenesis, BEAS-2B cells were infected with adenovirus
carrying catalase, a scavenger of hydrogen peroxide, or GFP (as
control) at 20 MOI. These cells were treated by arsenic and used
for angiogenesis assay as previously described. Overexpression of
catalase in arsenic-treated BEAS-2B cells significantly decreased
angiogenesis when compared to the control group (Fig. 4C). These
results indicate that arsenic induces ROS production which is
required for arsenic-inducing angiogenesis.
ROS induction is required for arsenic-induced AKT and
ERK1/2 activation and HIF-1 expression; and HIF-1
elevation is required for arsenic-induced angiogenesis
To explore the molecular mechanism of ROS in mediating
angiogenesis, we showed that ROS inhibitors DPI and catalase
significantly suppressed AKT and ERK1/2 activation (Fig. 5A).
Similarly, the expression of HIF-1a was decreased by ROS
inhibitors (Fig. 5A). To determine whether HIF-1a elevation is
required for arsenic-induced angiogenesis, BEAS-2B cells were
transduced by adenovirus carrying siHIF-1a or GFP. These cells
Figure 1. Arsenic induced angiogenesis. (A) A549 cells were treated without or with 5 mM of arsenic (As) for 5 h, then trypsinized, resuspended
in serum-free medium (3610
7cells/ml, 0.1 ml), and mixed in 1:1 ratio with Matrigel (Collaborative Biomedical Products, Bedford, MA). Aliquots of the
mixture were then implanted onto the CAM of 9-day-old embryos. After 96 h incubation, the area around the implanted Matrigel was photographed
with a Nikon digital camera. Bar: 2 mm (upper panel). The number of blood vessels was obtained by counting the branching of blood vessels, and the
relative angiogenesis was obtained by normalizing to that of the control without arsenic treatment. The data represent the mean 6 SD of the relative
angiogenesis from eight different embryos (bottom panel). *, indicates that the relative angiogenesis index significantly increased in arsenic
treatment group when compared with control group, P,0.05. (B) BEAS-2B cells were treated with or without arsenic to perform tumor angiogenesis
assay as above. Bar: 2 mm. *, indicates that the relative angiogenesis index significantly increased in arsenic treatment group when compared with
control group, P,0.05.
doi:10.1371/journal.pone.0020858.g001
Arsenic Induces Angiogenesis via ROS
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20858were treated by arsenic to perform angiogenesis assay as above. As
shown in Fig. 5B, HIF-1a knockdown markedly inhibited the
angiogenesis with the reduction of angiogenesis responses by 50%.
These results suggest that arsenic induces HIF-1 expression
through ROS generation, AKT and ERK1/2 activation, and
HIF-1 elevation is required for arsenic-induced angiogenesis.
ROS production is required for arsenic-induced VEGF
expression, and VEGF is required for arsenic-induced
angiogenesis
It is known that HIF-1 induces VEGF transcription by the binding
of HIF-1 to VEGF promoter [29]. Both HIF-1 and VEGF play a
pivotal role in regulating anigogenesis [17]. To determine whether
ROS are required for arsenic-induced VEGF expression, the cells
were pretreated with DPI and catalase, followed by the arsenic
treatment. DPI and catalase suppressed arsenic-induced VEGF
expression (Fig. 6A). To assess whether VEGF expression is required
for arsenic-induced angiogenesis, the cells were transfected with
VEGF siRNA or scrambled siRNA control, followed by the
treatment of arsenic. These treated cells were used to perform
angiogenesis assay. Similar to the results of HIF-1a knockdown,
VEGF knockdown also decreased arsenic-induced angiogenesis by
50% (Fig. 6B), suggesting that arsenic can increase HIF-1 expression,
which in turn regulates VEGF expression for inducing angiogenesis.
Figure 2. Arsenic treatment induced phospho-AKT and phospho-ERK1/2 activation, and increased HIF-1a and VEGF expression. (A)
A549 and BEAS-2B cells were treated with different doses of arsenic (As) for 6 h, total proteins are subjected to Western blotting for HIF-1a and HIF-
1b expression. A549 and BEAS-2B cells were cultured in serum-free medium for 24 h, then treated with different doses of arsenic for 2 h. Total
proteins were subjected to Western blotting analysis for the levels of phospho-AKT, total AKT, phospho-ERK1/2, and ERK2 expression (upper panel).
Relative densities of p-AKT, p-ERK1/2 and HIF-1a were analyzed by the ratio of p-AKT/AKT, p-ERK1/2/ERK2 and HIF-1a/HIF-1b using ImageJ software
and normalized to those of control cells. The data represents the mean6 SD from duplicate experiments (bottom panel). *, indicates significant
increase when compared with the control cells, P,0.05. (B) BEAS-2B cells were seeded in 12-well plate. Cells were co-transfected with VEGF reporter
and b-galactosidase (b-gal) plasmids and cultured for 15 h. Arsenic at 0, 2.5, and 5 mM was added for 24 h. Luciferase assay was performed by using
luciferase assay system. The activity of b-gal was used as internal control of transfection efficiency. The relative luciferase activity was calculated as the
ratio of luciferase/b-gal activity, and normalized to the control group. *, indicates that the relative luc activity significantly increased in arsenic
treatment group when compared with the control group, P,0.05. C, BEAS-2B cells were treated without or with 5 mM of arsenic for 24 h. Total RNAs
were extracted by Trizol and subjected to RT-PCR analysis of VEGF and GAPDH expression.
doi:10.1371/journal.pone.0020858.g002
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Environmental exposure to arsenic is commonly in the forms of
either arsenite (As
+3) or arsenate (As
+5), which is widely present in
environments such as water, air and soil. Arsenite is the pre-
dominant form of arsenic in contaminated water and is the form
mainly attributed to the induction of human cancers, including
lung, skin, bladder, and liver cancer. People are exposed to arsenic
through the arsenic-containing drinking water, food, and air-dust.
The occupational exposure to arsenic may be through the
inhalation of arsenic dusts in the production and distribution
process. There are more than 1.5 million industrial workers that
are potentially exposed to arsenic and arsenic compounds during
the product manufacturing and distribution according to the
NIOSH estimate [31]. Lung is one of the major organs to arsenic
exposure. As a metalloid carcinogen, arsenic is known to be
associated with higher incidence of both lung cancer and non-
malignant pulmonary diseases. In this study, we used sodium
arsenic to treat both human lung adenocarcinoma cells A549 and
immortalized human lung epithelial cells, BEAS-2B; and demon-
strated that short time exposure of arsenic in lung epithelial cells
induced angiogenesis, suggesting that arsenic-inducing angiogen-
esis is involved in arsenic-inducing lung carcinogenesis.
ROS include superoxide, hydrogen peroxide and hydroxyl
radical. Previous studies demonstrated that arsenic induced ROS
production and DNA damage [4,32-34]. We found that arsenic
induced ROS production in a dose-dependent manner, and that
suppression of ROS generation by catalase inhibited arsenic-
inducing angiogenesis, suggesting that ROS production is required
for arsenic-inducing angiogenesis.
In this study, we showed that arsenic treatment led to the
induction of VEGF and HIF-1 expression. HIF-1 composes of the
Figure 3. AKT and ERK1/2 pathways are required for arsenic-inducing HIF-1a expression and angiogenesis. (A) BEAS-2B cells were
cultured in serum-free medium for 24 h, then cells were pre-treated with LY294002 or U0126 at 20 mM for 30 min. Arsenic at 5 mM was added to the
cells for 2 h (for p-AKT, AKT, p-ERK1/2, and ERK2 expression) and 6 h (for HIF-1a and HIF-1b expression), respectively. Total proteins were analyzed by
Western blotting to detect the expression of proteins as indicated (left panel). Relative densities of p-AKT, p-ERK1/2 and HIF-1a were analyzed as Fig.
2A (right panel). *, indicates significant increase when compared with the control cells, P,0.05. . #, indicates significant decrease when compared
with the sodium arsenite treatment, P,0.05. (B) BEAS-2B cells were treated with 5 mM of arsenic. Cells were trypsinized, mixed with equal volume of
Matrigel with or without 15 mM of LY294002 or U0126. Equal volume of DMSO was added as a negative control. Angiogenesis assay was performed
as described in Fig. 1. *, indicates that the relative angiogenesis index was significantly decreased when compared with DMSO control group, P,0.05.
(C) BEAS-2B cells were infected with adenovirus carrying GFP (Ad-GFP) or AKT dominant negative (Ad-AKT-DN) at 20 MOI (upper panel), or
transfected with scrambled control of siRNA (siScramble) or siMAPK at 50 nM (bottom panel). After 24 h, cells were treated with arsenic and
angiogenesis assay was performed as above. *, indicates that the relative angiogenesis index was significantly decreased when compared with Ad-
GFP or siScramble control group, P,0.05.
doi:10.1371/journal.pone.0020858.g003
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well plates. Cells were treated with different doses of arsenic as indicated in serum-free medium. DCFH-DA at 5 mM was added to the cells for 15 min.
Then the cells were washed and fixed, and the fluorescent images were captured using a fluorescent microscope (upper panel). The corresponding
phase micrographs were shown in the bottom panel. (B) BEAS-2B cells were seeded into the 6-well plate. The cells were then cultured in serum-free
medium with arsenic at 5 mM for different time points as indicated. DCFH-DA staining was performed as above. (C) BEAS-2B cells were infected with
adenovirus carrying GFP (Ad-GFP) and catalase (Ad-catalase), respectively at 20 MOI. After 24 h, cells were treated with 5 mM arsenic for 5 h to
perform angiogenesis assay. *, indicates that the relative angiogenesis index was significantly decreased when compared with Ad-GFP control group,
P,0.05.
doi:10.1371/journal.pone.0020858.g004
Figure 5. ROS are required for AKT and ERK1/2 activation, HIF-1a expression, and angiogenesis. (A) BEAS-2B cells were cultured in
serum-free medium for 24 h, then cells were pre-treated with DPI or catalase for 30 min. Arsenic at 5 mM was added to the cells for 2 h or 6 h as
above. The specific proteins are analyzed by Western blotting (left panel). The relative densities of p-AKT, p-ERK1/2 and HIF-1a were determined as
above. *, indicates significant increase when compared with the control cells, P,0.05. . #, indicates significant decrease when compared with the
sodium arsenite treatment alone, P,0.05. (B) BEAS-2B cells were infected with adenovirus carrying GFP and HIF-1a siRNA (Ad-GFP and Ad-siHIF-1a,
respectively) at 20 MOI for 24 h, then the cells were treated with 5 mM arsenic for 5 h and angiogenesis assay was performed as above. *, indicates
that the relative angiogenesis index was significantly decreased when compared with the control group, P,0.05.
doi:10.1371/journal.pone.0020858.g005
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VEGF expression at transcriptional level. VEGF is a key
angiogenesis factor for stimulating endothelial cell growth and
angiogenesis [35,36]. Inhibition of VEGF-inducing angiogenesis
greatly decreased tumor growth in vivo [37]. In chronic pulmonary
diseases such as COPD, pulmonary endothelial dysfunction and
change of levels of VEGF and its receptor were found to be
involved in the development of vascular disease [38,39]. HIF-1
also regulates many other target genes that are involved in crucial
aspects of cancer biology including angiogenesis [28]. Overex-
pression of HIF-1 is a hallmark of many kinds of solid tumors, and
is also associated with skeletal muscle disease COPD [28,40,41].
Recent study showed that chronic exposure to low-dose As
+3
stimulated tumor growth through induction of angiogenesis [42].
This study showed that the knockdown of HIF-1 and VEGF using
siRNAs against HIF-1a or VEGF inhibited arsenic-inducing
angiogenesis, demonstrating the important role of HIF-1a and
VEGF in arsenic-inducing angiogenesis.
To further determine the signaling pathways in upregulating
HIF-1 and VEGF expression, we found that AKT and ERK1/2
were activated by arsenic, and that inhibition of AKT or ERK1/2
by their chemical inhibitors, dominant negative molecule, or
siRNAs blocked arsenic-inducing angiogenesis. These findings
suggest that AKT and ERK pathways are involved in arsenic-
stimulating angiogenesis in lung epithelial cells, which is consistent
with previous study showing that arsenic induced ROS generation
and ERK activation [4]. This study reveals the important
biological function of the previous observation by our lab and
others that showed AKT and ERK are upstream regulators of
HIF-1 and VEGF [27,43–45]. We further demonstrated that
inhibition of ROS generation blocked HIF-1 and VEGF induc-
tion, AKT and ERK1/2 activation, and angiogenesis in response
to arsenic treatment. This new result provides an important link
from ROS, signaling molecules, to angiogenesis. In addition to
acute treatment of arsenic, we found that chronic treatment with
sodium arsenite had similar effects.
Taken together, this study demonstrated that acute treatment of
arsenic in lung epithelial cells induced angiogenesis, arsenic
increases ROS induction for inducing angiogenesis, and ROS
transmits the angiogenesis signals to downstream targets AKT,
ERK1/2, HIF-1, and VEGF. This study shows a novel molecular
mechanism of arsenic in affecting human lung epithelial cells to
induce angiogenesis. This finding may provide useful information
for developing mechanism-based prevention and treatment of lung
cancer induced by arsenic in the future.
Author Contributions
Conceived and designed the experiments: BHJ LZL. Performed the
experiments: LZL Yue Jiang RLC Yi Jing. Analyzed the data: Yue Jiang
LZL RLC. Contributed reagents/materials/analysis tools: SCP. Wrote the
paper: LZL SCP BHJ.
References
1. Brown LM, Pottern LM, Blot WJ (1984) Lung cancer in relation to
environmental pollutants emitted from industrial sources. Environ Res 34:
250–261.
2. Knobeloch LM, Zierold KM, Anderson HA (2006) Association of arsenic-
contaminated drinking-water with prevalence of skin cancer in Wisconsin’s Fox
River Valley. J Health Popul Nutr 24: 206–213.
Figure 6. VEGF is required for arsenic-inducing angiogenesis. (A) BEAS-2B cells were treated with DPI or catalase for 30 min, then with 5 mM
arsenic for 24 h. Total RNAs were extracted by Trizol, and analyzed by RT-PCR for VEGF and GAPDH expression (upper panel). Relative density of VEGF
was analyzed by the ratio of VEGF/GAPDH using ImageJ software and normalized to control cells. The data represents the mean6 SD from duplicate
experiments (bottom panel). *, indicates significant increase when compared with the control cells, P,0.05. . #, indicates significant decrease when
compared with the sodium arsenite treatment alone, P,0.05. (B) BEAS-2B cells were transfected with VEGF siRNA and scrambled siRNA (siVEGF and
siScramble, respectively). After the transfection for 24 h, cells were treated with 5 mM arsenic for 5 h to perform angiogenesis assay. *, indicates that
the relative angiogenesis index was significantly decreased in siVEGF treatment group when compared with siScramble group, P,0.05.
doi:10.1371/journal.pone.0020858.g006
Arsenic Induces Angiogenesis via ROS
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e208583. Waalkes MP, Ward JM, Diwan BA (2004) Induction of tumors of the liver, lung,
ovary and adrenal in adult mice after brief maternal gestational exposure to
inorganic arsenic: promotional effects of postnatal phorbol ester exposure on
hepatic and pulmonary, but not dermal cancers. Carcinogenesis 25: 133–141.
4. Chowdhury R, Chatterjee R, Giri AK, Mandal C, Chaudhuri K (2010) Arsenic-
induced cell proliferation is associated with enhanced ROS generation, Erk
signaling and CyclinA expression. Toxicol Lett 198: 263–271.
5. Davey JC, Bodwell JE, Gosse JA, Hamilton JW (2007) Arsenic as an endocrine
disruptor: effects of arsenic on estrogen receptor-mediated gene expression in
vivo and in cell culture. Toxicol Sci 98: 75–86.
6. Dong JT, Luo XM (1993) Arsenic-induced DNA-strand breaks associated with
DNA-protein crosslinks in human fetal lung fibroblasts. Mutat Res 302: 97–102.
7. Reichard JF, Schnekenburger M, Puga A (2007) A Long term low-dose arsenic
exposure induces loss of DNA methylation. Biochem Biophys Res Commun 352:
188–192.
8. Shi H, Hudson LG, Ding W, Wang S, Cooper KL, et al. (2004) Arsenic causes
DNA damage in keratinocytes via generation of hydroxyl radicals. Chem Res
Toxicol 17: 871–878.
9. Li G, Lee LS, Li M, Tsao SW, Chiu JF (2011) Molecular changes during
arsenic-induced cell transformation. J Cell Physiol.
10. Huang C, Ke Q, Costa M, Shi X (2004) Molecular mechanisms of arsenic
carcinogenesis. Mol Cell Biochem 255: 57–66.
11. Ying S, Myers K, Bottomley S, Helleday T, Bryant HE (2009) BRCA2-
dependent homologous recombination is required for repair of Arsenic-induced
replication lesions in mammalian cells. Nucleic Acids Res 37: 5105–5113.
12. Lee L, Bebb G (2005) A case of Bowen’s disease and small-cell lung carcinoma:
long-term consequences of chronic arsenic exposure in Chinese traditional
medicine. Environ Health Perspect 113: 207–210.
13. Neuberger JS, Field RW (2003) Occupation and lung cancer in nonsmokers.
Rev Environ Health 18: 251–267.
14. Guha Mazumder DN (2007) Arsenic and non-malignant lung disease. J Environ
Sci Health A Tox. Hazard Subst Environ Eng 42: 1859–1867.
15. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature
407: 249–257.
16. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med
285: 1182–1186.
17. Folkman, J (2006) Angiogenesis. Annu. Rev. Med 57: 1–18.
18. Voelkel NF, Douglas IS, Nicolls M (2007) Angiogenesis in chronic lung disease.
Chest 131: 874–879.
19. Walters EH, Reid D, Soltani A, Ward C (2008) Angiogenesis: a potentially
critical part of remodelling in chronic airway diseases? Pharmacol Ther 118:
128–137.
20. Gao N, Shen L, Zhang Z, Leonard SS, He H, et al. (2004) Arsenic induces HIF-
1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145
human prostate carcinoma cells. Mol Cell Biochem 255: 33–45.
21. Skinner HD, Zhong XS, Gao N, Shi X, Jiang BH (2004) Arsenic induces
p70S6K1 activation and HIF-1alpha expression in prostate cancer cells. Mol
Cell Biochem 255: 19–23.
22. Meng D, Wang X, Chang Q, Hitron A, Zhang Z, et al. (2010) Arsenic promotes
angiogenesis in vitro via a heme oxygenase-1-dependent mechanism. Toxicol
Appl. Pharmacol 244: 291–299.
23. Mousa SA, O’Connor L, Rossman TG, Block E (2007) Pro-angiogenesis action
of arsenic and its reversal by selenium-derived compounds. Carcinogenesis 28:
962–967.
24. Straub AC, Klei LR, Stolz DB, Barchowsky A (2009) Arsenic requires
sphingosine-1-phosphate type 1 receptors to induce angiogenic genes and
endothelial cell remodeling. Am J Pathol 174: 1949–1958.
25. Jiang BH, Zheng JZ, Aoki M, Vogt PK (2000) Phosphatidylinositol 3-kinase
signaling mediates angiogenesis and expression of vascular endothelial growth
factor in endothelial cells. Proc Natl Acad Sci U S A 97: 1749–1753.
26. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, et al. (2007) Reactive
oxygen species regulate angiogenesis and tumor growth through vascular
endothelial growth factor. Cancer Res 67: 10823–10830.
27. Liu LZ, Hu XW, Xia C, He J, Zhou Q, et al. (2006) Reactive oxygen species
regulate epidermal growth factor-induced vascular endothelial growth factor and
hypoxia-inducible factor-1alpha expression through activation of AKT and
P70S6K1 in human ovarian cancer cells. Free Radic Biol Med 41: 1521–1533.
28. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:
721–732.
29. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of
vascular endothelial growth factor gene transcription by hypoxia-inducible factor
1. Mol Cell Biol 16: 4604–4613.
30. Pi J, He Y, Bortner C, Huang J, Liu J, et al. (2005) Low level, long-term
inorganic arsenic exposure causes generalized resistance to apoptosis in cultured
human keratinocytes: potential role in skin co-carcinogenesis. Int J Cancer 116:
20–26.
31. Stohrer G (1991) Arsenic: opportunity for risk assessment. Arch Toxicol 65:
525–531.
32. Ding W, Hudson LG, Liu KJ (2005) Inorganic arsenic compounds cause
oxidative damage to DNA and protein by inducing ROS and RNS generation in
human keratinocytes. Mol Cell Biochem 279: 105–112.
33. Cooper KL, Liu KJ, Hudson LG (2009) Enhanced ROS production and redox
signaling with combined arsenite and UVA exposure: contribution of NADPH
oxidase. Free Radic Biol Med 47: 381–388.
34. Sampayo-Reyes A, Hernandez A, El Yamani N, Lopez-Campos C, Mayet-
Machado E, et al. (2010) Arsenic induces DNA damage in environmentally
exposed Mexican children and adults. Influence of GSTO1 and AS3MT
polymorphisms. Toxicol Sci 117: 63–71.
35. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, et al. (1989)
Tumor vascular permeability factor stimulates endothelial cell growth and
angiogenesis. J Clin Invest 84: 1470–1478.
36. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular
endothelial growth factor is a secreted angiogenic mitogen. Science 246:
1306–1309.
37. Kim KJ, Li B, Winer J, Armanini M, Gillett N, et al. (1993) Inhibition of
vascular endothelial growth factor-induced angiogenesis suppresses tumour
growth in vivo. Nature 362: 841–844.
38. Kierszniewska-Stepien D, Pietras T, Gorski P, Stepien H (2006) Serum vascular
endothelial growth factor and its receptor level in patients with chronic
obstructive pulmonary disease. Eur Cytokine Netw 17: 75–79.
39. Yang Q, Underwood MJ, Hsin MK, Liu XC, He GW (2008) Dysfunction of
pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic
considerations for future drug development. Curr Drug Metab 9: 661–667.
40. Jatta K, Eliason G, Portela-Gomes GM, Grimelius L, Caro O, et al. (2009)
Overexpression of von Hippel-Lindau protein in skeletal muscles of patients with
chronic obstructive pulmonary disease. J Clin Pathol 62: 70–76.
41. Hasaneen NA, Zucker S, Lin RZ, Vaday GG, Panettieri RA, et al. (2007)
Angiogenesis is induced by airway smooth muscle strain. Am J Physiol Lung Cell
Mol Physiol 293: L1059–L1068.
42. Kamat CD, Green DE, Curilla S, Warnke L, Hamilton JW, et al. (2005) Role of
HIF signaling on tumorigenesis in response to chronic low-dose arsenic
administration. Toxicol. Sci. 86: 248–257.
43. Mottet D, Michel G, Renard P, Ninane N, Raes M, et al. (2003) Role of ERK
and calcium in the hypoxia-induced activation of HIF-1. J Cell Physiol 194:
30–44.
44. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, et al. (2000)
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal
growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in
human prostate cancer cells: implications for tumor angiogenesis and
therapeutics. Cancer Res 60: 1541–1545.
45. Zhou Q, Liu LZ, Fu B, Hu X, Shi X, et al. (2007) Reactive oxygen species
regulate insulin-induced VEGF and HIF-1alpha expression through the
activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 28:
28–37.
Arsenic Induces Angiogenesis via ROS
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20858